These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16291374)

  • 1. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children.
    Cesaro S; Bisogno G; Pusiol A
    J Pediatr; 2005 Nov; 147(5):715; author reply 715-6. PubMed ID: 16291374
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
    Taube T; Schmid H; Reinhard H; von Stackelberg A; Overberg US
    Haematologica; 2005 Feb; 90(2):281-3. PubMed ID: 15710595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
    Citak EC; Citak FE
    J Trop Pediatr; 2011 Feb; 57(1):71-2. PubMed ID: 20463085
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
    Bengtson KL; Skinner MA; Ware RE
    J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment for symptomatic chronic ITP.
    Tamminga RY; Bruin MC
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):714-6. PubMed ID: 16933264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
    Introna M; Golay J; Barbui T
    Haematologica; 2003 May; 88(5):482-4. PubMed ID: 12745265
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the management of chronic immune thrombocytopenic purpura: what is its place?
    Ducassou S; Aladjidi N; Lutz P
    Pediatr Blood Cancer; 2010 Apr; 54(4):632. PubMed ID: 19953650
    [No Abstract]   [Full Text] [Related]  

  • 12. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N; Evangelista ML; Amadori S; Stasi R
    Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy.
    Toffoletti E; Zaja F; Chiarvesio A; Michelutti A; Battista M; Fanin R
    Haematologica; 2008 May; 93(5):795-6. PubMed ID: 18450740
    [No Abstract]   [Full Text] [Related]  

  • 14. Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura.
    Stübgen JP
    J Neurol Sci; 2010 Jan; 288(1-2):178-81. PubMed ID: 19897212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of rituximab in chronic childhood immune thrombocytopenic purpura.
    Bay A; Oner AF; Uner A; Dogan M
    Pediatr Int; 2006 Oct; 48(5):514-6. PubMed ID: 16970796
    [No Abstract]   [Full Text] [Related]  

  • 16. Transient response to multiple courses of pulse high-dose dexamethasone therapy in children with idiopathic thrombocytopenic purpura.
    Eskenazi AE; Louie J
    Haematologia (Budap); 1998; 29(2):81-7. PubMed ID: 9728800
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
    Parodi E; Rivetti E; Amendola G; Bisogno G; Calabrese R; Farruggia P; Giordano P; Matarese SM; Nardi M; Nobili B; Notarangelo LD; Russo G; Vimercati C; Zecca M; De Mattia D; Ramenghi U
    Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
    Kuwana M; Iki S; Urabe A
    Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab.
    Iesato K; Hatakeyama N; Yamamoto M; Hori T; Inazawa N; Tsutsumi H; Suzuki N
    Pediatr Blood Cancer; 2009 Aug; 53(2):203-5. PubMed ID: 19301247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura.
    Koene HR
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):703-5. PubMed ID: 16933273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.